How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) announced its quarterly earnings data on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

When did Cardiff Oncology's stock split?

Shares of Cardiff Oncology reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA) , Inovio Pharmaceuticals (INO) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , OPKO Health (OPK) , Alnylam Pharmaceuticals (ALNY) , Alibaba Group (BABA) , Zynerba Pharmaceuticals (ZYNE) , Amarin (AMRN) and Idera Pharmaceuticals (IDRA) .

Cardiff Oncology Stock Price, News & Analysis (NASDAQ:TROV)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.20
▼
$1.27
50-Day Range: $1.19
▼
$24.71
52-Week Range: $0.70
▼
$3.46

Volume: 127,159 shs
Average Volume: 648,892 shs
Market Capitalization: $13.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Social Media

About Cardiff Oncology Stock (NASDAQ:TROV)

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

September 29, 2023 | markets.businessinsider.com

Cardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating Recommendation

September 26, 2023 | marketwatch.com

Stocks to Watch: MillerKnoll, Cardiff Oncology, Morphic Holdings

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 8, 2023 | marketwatch.com

Cardiff Oncology Shares Up 26% After Potential Cancer Treatment Advances

August 8, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)

May 27, 2023 | fool.com

Cardiff Oncology (NASDAQ: CRDF)

January 13, 2023 | forbes.com

Cardiff Oncology

December 14, 2022 | seekingalpha.com

Cardiff Oncology: Staying The Course

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 16, 2022 | markets.businessinsider.com

Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying

September 29, 2022 | finance.yahoo.com

Cardiff Oncology, Inc. (CRDF)

September 24, 2022 | seekingalpha.com

CRDF Cardiff Oncology, Inc.

August 25, 2022 | msn.com

Looking Into Cardiff Oncology's Return On Capital Employed

August 22, 2022 | seekingalpha.com

Cardiff Oncology: Down But Not Out

July 28, 2022 | finance.yahoo.com

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 31, 2022 | stocknews.com

5 Oncology Stocks Wall Street Predicts Will Rally 135% or More

March 22, 2022 | prnewswire.com

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

August 5, 2021 | prnewswire.com

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

April 8, 2021 | prnewswire.com

Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

October 20, 2020 | finance.yahoo.com

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance

October 15, 2020 | news.yahoo.com

Nautilus Biotechnology Appoints Nick Nelson as Chief Business Officer

October 13, 2020 | seekingalpha.com

List Of Concerns About Cardiff Oncology's Plk1 Inhibitor - Seeking Alpha

October 9, 2020 | streetinsider.com

BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering - StreetInsider.com

September 30, 2020 | marketwatch.com

Global Cell-Free DNA Testing Market Phenomenal Growth Prospects, Opportunities, SWOT Study and Volume| Agilent Technology, Allenex, Biocept

September 29, 2020 | prnewswire.com

Cardiff Oncology Announces Proposed Public Offering - PRNewswire

September 29, 2020 | marketwatch.com

Liquid Biopsy Market Size 2020 : Top Manufacturers, Industry Share, Regional Analysis, Types and Applications and Forecasts to 2025

September 29, 2020 | marketwatch.com

Europe Liquid Biopsy Market Size, Growth, Opportunity and Forecast to 2025

See More Headlines

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2020
Today: 11/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TROV
CUSIP: N/A
CIK: 1213037
Web: www.trovagene.com
Phone: (858) 952-7570
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,410,000.00
Net Margins: -3,688.31%
Pretax Margin: N/A
Return on Equity: -202.00%
Return on Assets: -122.92%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 2.37
Quick Ratio: 2.37

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 55.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.94 per share
Price / Book: 1.33

Miscellaneous

Outstanding Shares: 11,011,000
Free Float: N/A
Market Cap: $13.76 million
Optionable: Not Optionable
Beta: 1.04

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mark Erlander
Chief Executive Officer & Director
Vicki Kelemen
Chief Operating Officer & Executive Vice President
Brigitte Lindsay
Secretary & Vice President-Finance

Key Competitors

View All Competitors

TROV Stock Analysis - Frequently Asked Questions

How were Cardiff Oncology's earnings last quarter?: Cardiff Oncology, Inc. (NASDAQ:TROV) announced its quarterly earnings data on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.
When did Cardiff Oncology's stock split?: Shares of Cardiff Oncology reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What other stocks do shareholders of Cardiff Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:TROV) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cardiff Oncology Stock Price, News & Analysis (NASDAQ:TROV)

About Cardiff Oncology Stock (NASDAQ:TROV)

TROV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TROV Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info